Product Description
Adenosine monophosphate, also known as 5'-adenylic acid and abbreviated AMP, is a nucleotide that is found in RNA. AMP is used as a dietary supplement to boost immune activity, and is also used as a substitute sweetener to aid in the maintenance of a low-calorie diet. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Adenosine-monophosphate#section=Pharmacology-and-Biochemistry)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant, Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Pakistan | Russia | Taiwan | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Danish Headache Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500097771 |
ChiCTR2500097771 | N/A |
Not yet recruiting |
Anemia |
2026-06-06 |
|||
ChiCTR2400089222 |
ChiCTR2400089222 | N/A |
Not yet recruiting |
Anemia|Intestinal Diseases|Cesarean Section |
2025-08-31 |
|||
NCT01471990 |
H-1-2011-023 | N/A |
Completed |
Migraine without Aura|Migraine with Aura|Migraine Disorders |
2012-06-01 |
2019-03-19 |
Treatments |
|
CTR20233188 |
CTR20233188 | N/A |
Not yet recruiting |
Insulin Resistance |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
ACTRN12613000038796 |
ACTRN12613000038796 | N/A |
Completed |
Asthma |
None |
2024-08-29 |
Treatments |
|
ACTRN12606000488505 |
ACTRN12606000488505 | P4 |
Completed |
Asthma |
2008-11-28 |
2024-08-29 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/12/2025 |
News Article |
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways |
|
12/10/2025 |
News Article |
Poxel Publishes Its Financial Results for the First Half of 2025 |
|
12/10/2025 |
News Article |
Consumers report feeling lighter, more motivated, mindful, and happier with Montoloeder's Metabolaid® weight-control formulation |
|
11/13/2025 |
News Article |
Poxel Reports Revenue for the Third Quarter 2025 |
|
05/15/2024 |
PubMed |
An Enzymatic Prodrug-like Route to Thio and Selenoamides. |
|
05/15/2024 |
PubMed |
Caenorhabditis elegans Dicer acts with the RIG-I-like helicase DRH-1 and RDE-4 to cleave dsRNA. |
|
07/01/2024 |
PubMed |
Presynaptic structural and functional plasticity are coupled by convergent Rap1 signaling. |